Insider Selling: Bioventus Inc. (NYSE:BVS) SVP Sells 2,535 Shares of Stock

by · The Cerbat Gem

Bioventus Inc. (NYSE:BVS – Get Free Report) SVP Katrina J. Church sold 2,535 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $10.53, for a total value of $26,693.55. Following the completion of the transaction, the senior vice president now owns 47,264 shares of the company’s stock, valued at approximately $497,689.92. This represents a 5.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Bioventus Trading Down 3.5 %

Shares of NYSE BVS opened at $10.62 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. The stock’s 50 day moving average price is $11.81 and its two-hundred day moving average price is $9.80. Bioventus Inc. has a 52-week low of $3.90 and a 52-week high of $14.38. The stock has a market capitalization of $861.87 million, a P/E ratio of -17.41 and a beta of 0.79.

Bioventus (NYSE:BVS – Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. The firm had revenue of $138.96 million for the quarter, compared to analysts’ expectations of $132.57 million. During the same period last year, the business posted $0.05 earnings per share. On average, analysts anticipate that Bioventus Inc. will post 0.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Craig Hallum boosted their target price on shares of Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, September 27th. Canaccord Genuity Group boosted their price objective on shares of Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and raised their target price for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Read Our Latest Report on Bioventus

Hedge Funds Weigh In On Bioventus

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in Bioventus by 7.5% in the third quarter. Geode Capital Management LLC now owns 940,496 shares of the company’s stock worth $11,241,000 after buying an additional 65,374 shares during the period. Royce & Associates LP bought a new position in shares of Bioventus during the third quarter worth about $8,337,000. State Street Corp increased its holdings in shares of Bioventus by 38.8% in the 3rd quarter. State Street Corp now owns 676,501 shares of the company’s stock worth $8,084,000 after acquiring an additional 189,216 shares during the period. Renaissance Technologies LLC lifted its position in Bioventus by 401.5% in the 2nd quarter. Renaissance Technologies LLC now owns 503,175 shares of the company’s stock valued at $2,893,000 after purchasing an additional 402,841 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Bioventus by 38.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company’s stock valued at $4,662,000 after purchasing an additional 109,359 shares during the last quarter. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Company Profile

(Get Free Report)

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.

See Also